2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, AML, Translational Research, CML, Study Population, Human, Animal Model
PAPER

4972 Chronic inflammation in bone marrow immune microenvironment of -7/7q- myeloid neoplasm due to haploinsufficiency of FGL2

Kejing Li, Ruoyang Shao, MD, PhD2, Zhonghui Jiang3, Zinan Feng4, Yu Zhang5, Pengcheng SHI6, Sijian Yu7, Hui Liu8, Ling Jiang9, MIN Dai10, Qifa Liu, MD11, Xuan Li, PhD12
1 Nanfang Hospital, Southern Medical University, Guangzhou, China
2 Nanfang Hospital, Southern Medical University, Guangzhou, China
3 Nanfang Hospital, Southern Medical University, Guangzhou, China
4 Nanfang Hospital, Southern Medical University, Guangzhou, China
5 Nanfang Hospital, Southern Medical University, Guangzhou, China
6 Nanfang Hospital, Southern Medical University, Guangzhou, China
7 Nanfang Hospital, Southern Medical University, Guangzhou, China
8 Nanfang Hospital, Southern Medical University, Guangzhou, China
9 Nanfang Hospital, Southern Medical University, Guangzhou, China
10 Nanfang Hospital, Southern Medical University, Guangzhou, China
11 Nanfang Hospital, Southern Medical University, Guangzhou, China
12 Nanfang Hospital, Southern Medical University, Guangzhou, China

The -7/7q- is one of the high-risk cytogenetic abnormalities, which is associated with dismal prognosis in myeloid neoplasms. The Fibrinogen-like protein 2 (FGL2) gene, mapped to 7q11.23, has been suggested to possess immunomodulatory activity. Chronic inflammation within the bone marrow microenvironment is a recognized core mechanism driving the initiation, progression, and therapy resistance of myeloid malignancies. This study intends to explore whether and how FGL2 haploinsufficiency drives chronic inflammation in the bone marrow microenvironment of -7/7q- myeloid neoplasms, thereby contributing to their poor prognosis.

Bone marrow samples were collected from a total of 28 patients with myeloid neoplasms for single-cell transcriptome sequencing (scRNA-seq), including 14 with -7/7q- abnormalities and 14 with normal karyotypes. Each subgroup had 9 with myelodysplastic syndrome (MDS), 2 with secondary acute myeloid leukemia (sAML) evolving from MDS, and 3 with de novo AML. Differential gene expression analysis confirmed that tumor cells from -7/7q- patients had lower FGL2 expression compared with controls. These patients showed a lower FGL2–receptor interaction from tumor cells to immune cells than patients with normal karyotypes.

Through analysis of transcriptomic profiles, we identified chronic inflammation in patients with -7/7q- abnormalities. In patients with -7/7q- abnormalities, immune cells, particularly macrophages and CD14?monocytes, tended to have higher expression of pro-inflammatory cytokine genes (e.g., TNF, IL15). Enrichment analysis confirmed that these immune cells bore strong inflammatory and immune activation signatures. To validate whether this chronic inflammatory state was attributable to FGL2 haploinsufficiency, we established an FGL2-overexpression model using the -7-bearing MDS-L cell line, including a wild-type FGL2 complementation group (OE) and a vector-only control group (CTRL). We then performed co-culture experiments of the MDS-L cell line with macrophages and CD14? monocytes. After 24h co-culture, cells exposed to CTRL exhibited higher transcript levels of pro-inflammatory cytokines relative to those cultured with OE.

To explore the underlying mechanism of FGL2 haploinsufficiency-induced inflammation, we performed in vitro experiments on the signaling proteins suggested by scRNA-seq data. Western blot analysis indicated that ERK phosphorylation in the OE group was significantly higher than that in the CTRL group. Previously, ERK activation was also shown to possess anti-inflammatory effects. These results suggested a reduction in ERK activation might be associated with FGL2-mediated chronic inflammation. Moreover, scRNA-seq data also implied that FGL2 haploinsufficiency might influence the cell-intrinsic properties of neoplastic cells, including apoptosis evasion, enhanced proliferation and differentiation, and metabolic reprogramming.

In conclusion, FGL2 haploinsufficiency might contribute to chronic inflammation within the bone marrow microenvironment of -7/7q- myeloid neoplasms, via reduced ERK phosphorylation. The specific upstream and downstream regulatory mechanisms of the ERK pathway remain to be further elucidated.

Kejing Li: No relevant conflicts of interest to declare.